Table 1.

Case reports in the literature considering the results of trabectedin therapy in metastatic uLMS [26, 27, 28, 29, 30]

Authors [Ref.], year	Sarcoma type	Patients, n	Cycles of trabectedin	Response
Tavella et al. [26], 2017	Metastatic uLMS	1	30 cycles	Very good partial response, especially at the pulmonary and pancreatic levels, stable disease at the rest of metastatic sites
Bongiovanni et al. [27], 2015	Metastatic uLMS	1	22 cycles	Partial response with good tolerability, maintenance of the response for 10 months after trabectedin withdrawal
Corrado et al. [28], 2011	Metastatic uLMS	1	6 cycles	Prolonged clinical response in a heavily pretreated patient with lung metastases of uLMS, improvement of dyspnea symptoms, and acceptable toxicity profile
Amant et al. [29], 2009	Three patients with uLMS, 1 with uterine adenosarcoma, 1 with endometrial stromal sarcoma	5	25 cycles were administered (mean = 5; range: 2–12)	Partial response with clinical benefit was noted during 9 months in 1 patient (partial response in an epigastric mass and lung metastasis), whereas stable disease after 3 months was noted in 1 patient and progressive disease in 3 patients Taken together, the response rate was 1 out of 5 for all patients, and 1 out of 3 uLMS responded
Tewari et al. [30], 2006	Metastatic uLMS	1	12 cycles	A 38-year-old patient with an advanced, recurrent, and refractory uLMS (lung metastasis, pelvic progression) responded to trabectedin after failing 4 prior regimens (doxorubicin, gemcitabine, docetaxel, and ifosfamide) with a durable objective response lasting at least 8 months